- Corporate Officers - O
- O'connor Daniel J.
Insider Trading History of O'connor Daniel J.
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of O'connor Daniel J. since 2013.
This trader's CIK number is 1376847.
At the time of last reporting, O'connor Daniel J. was the President and CEO of Ambrx Biopharma, Inc.. (stock ticker symbol AMAM).
Also see all insider trading activities at Ambrx Biopharma, Inc..
Note that in the past
O'Connor Daniel J. also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Ambrx Biopharma, Inc. (AMAM) by O'connor Daniel J.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | AMAM | 0 | $0 | 50,012 | $491,117 | 0 | $0 |
Yearly summary of insider trading at Oncosec Medical Inc (ONCS) by O'connor Daniel J.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | ONCS | 0 | $0 | 3,413 | $26,314 | 0 | $0 |
| 2020 | ONCS | 0 | $0 | 12,142 | $36,294 | 0 | $0 |
| 2019 | ONCS | 0 | $0 | 2,128 | $4,596 | 0 | $0 |
| 2018 | ONCS | 26,667 | $34,100 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Ayala Pharmaceuticals, Inc. (ADXS) by O'connor Daniel J.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2016 | ADXS | 0 | $0 | 25,295 | $191,082 | 0 | $0 |
| 2015 | ADXS | 0 | $0 | 16,799 | $232,823 | 0 | $0 |
| 2014 | ADXS | 3,333 | $9,999 | 0 | $0 | 0 | $0 |
| 2013 | ADXS | 13,500 | $54,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Seelos Therapeutics, Inc. (SEEL) by O'connor Daniel J.
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | SEEL | 16,000 | $9,792 | 0 | $0 | 0 | $0 |
Insider trading activities at 4 companies by O'connor Daniel J.:
1. Ambrx Biopharma, Inc. (AMAM)
2. Oncosec Medical Inc (ONCS)
3. Ayala Pharmaceuticals, Inc. (ADXS)
4. Seelos Therapeutics, Inc. (SEEL)
Table 1. Insider trading of Ambrx Biopharma, Inc. (AMAM) by O'connor Daniel J.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-10-27 | AMAM | Sale | 50,012 | 9.82 | 491,117 |
Table 2. Insider trading of Oncosec Medical Inc (ONCS) by O'connor Daniel J.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-02-01 | ONCS | Sale | 3,413 | 7.71 | 26,314 |
| 2020-11-02 | ONCS | Sale | 3,280 | 3.79 | 12,431 |
| 2020-07-31 | ONCS | Sale | 3,133 | 4.20 | 13,158 |
| 2020-04-30 | ONCS | Sale | 3,075 | 1.79 | 5,504 |
| 2020-01-31 | ONCS | Sale | 2,654 | 1.96 | 5,201 |
| 2019-10-31 | ONCS | Sale | 2,128 | 2.16 | 4,596 |
| 2018-11-07 | ONCS | Buy | 10,000 | .91 | 9,100 |
| 2018-02-05 | ONCS | Buy | 16,667 | 1.50 | 25,000 |
Table 3. Insider trading of Ayala Pharmaceuticals, Inc. (ADXS) by O'connor Daniel J.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2016-11-02 | ADXS | Sale | 8,240 | 8.32 | 68,556 |
| 2016-05-02 | ADXS | Sale | 8,237 | 7.51 | 61,859 |
| 2016-01-29 | ADXS | Sale | 8,818 | 6.88 | 60,667 |
| 2015-10-30 | ADXS | Sale | 8,350 | 12.26 | 102,371 |
| 2015-07-31 | ADXS | Sale | 8,449 | 15.44 | 130,452 |
| 2014-03-31 | ADXS | Buy | 3,333 | 3.00 | 9,999 |
| 2013-10-24 | ADXS | Buy | 13,500 | 4.00 | 54,000 |
Table 4. Insider trading of Seelos Therapeutics, Inc. (SEEL) by O'connor Daniel J.
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2022-06-01 | SEEL | Buy | 16,000 | .61 | 9,792 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by O'connor Daniel J.
(President and CEO of Ambrx Biopharma, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.